patritumab deruxtecan

FDA grants priority review for Daiichi Sankyo-Merck’s lung cancer therapy
Pharmaceutical Business Review
Wed, 12/27/23 - 11:00 pm
Daiichi Sankyo
Merkc
patritumab deruxtecan
FDA
non-small cell lung cancer
FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag
Pharmaforum
Thu, 12/23/21 - 11:53 am
Daiichi Sankyo
FDA
antibody-drug conjugate
lung cancer
HER3
patritumab deruxtecan
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Pharmaceutical Business Review
Fri, 08/7/20 - 11:10 am
Daiichi Sankyo
AstraZeneca
patritumab deruxtecan
Tagrisso
non-small cell lung cancer
clinical trials